taurolidine is a broad spectrum antibacterial, antifungal and antiendotoxic drug. Is mainly used for preventing the junior symptoms of patients suffering from various blood stream infections related to the catheter. It can also be used for treating otitis, pleuropneumonia, osteomyelitis, dermatitis, periodontitis, gingivitis, acne, and ulcer. But have not been found to be useful against human papillomaviruses.

Disclosure of Invention

The invention aims to provide a new application of taurolidine, namely the application of taurolidine in inhibiting HPV virus or preparing anti-HPV virus medicaments.

It is preferable that: application of taurolidine in preparing medicaments for treating cervical epithelial cell neoplasia, vaginitis, cervical erosion, cervical polyp, cervical cancer or condyloma acuminatum caused by HPV virus infection.

In the technical scheme, the taurolidine can be prepared into injection, infusion solution, tablets, capsules and other dosage forms, and the infusion solution is preferred.

The invention has the beneficial effects that:

the invention discovers the new application of the taurolidine for the first time, namely the application of the taurolidine in inhibiting HPV virus or preparing anti-HPV virus medicaments. The safety of the taurolidine to human bodies is detected by clinical practice, the invention discovers the obvious drug effect of the taurolidine to HPV virus, provides powerful theoretical basis and practical basis for resisting the HPV virus, and has development value and popularization significance. The invention detects the inhibition effect of the taurolidine on the HPV virus at the cellular level, and provides a new way for treating diseases caused by the HPV virus.

Detailed Description

To better understand the essence of the present invention, the following was made by examining the inhibitory effect of taurolidine on HPV virus at the cellular level.

Firstly, experimental materials:

1.1 cells of human oral mucosal epithelial cells, derived from the virology research laboratory of the military veterinary institute;

1.2 strain Human Papilloma Virus (HPV), derived from the virology research laboratory of the military veterinary institute;

1.3 reagent elitec primary epithelial cell culture system PriMed-elitec-001, 0.25% trypsin, FBS, PBS (FH ═ 7.0);

1.4 instrument consumable pipettor and supporting suction head, 1.5mL centrifuging tube, ice box, ice machine, biological safety cabinet, carbon dioxide incubator.

II, an experimental method:

2.1 the cell culture recovers the epithelial cells of the oral mucosa of the human body, continuously transmits the cells for three generations, and is used for experimental research after the cells grow well;

2.2 Virus culture the preserved virus liquid is placed on ice to be slowly melted and then inoculated to a monolayer of human oral mucosa epithelial cells (no more than 24 hours), the culture is continued for 72 to 96 hours, and the virus liquid is harvested according to the cytopathic state. And determining the virus content as TCID₅₀The unit of calculation is/100. mu.L.

2.3 taurolidine inhibition

Drugs are mixed with virus and simultaneously inoculated into cells: digesting well-growing human oral mucosa epithelial cells with pancreatin, calculating cell content, inoculating to 96-well plate with 10 per well⁵Individual cells, seeded within 12 hours and in monolayer state for study of drug action. Inoculation virus content of 200 TCIDs₅₀HPV and taurolidine are mixed and immediately inoculated into a paved 6-well plate, and the 2 percent taurolidine solution and the drug dosage are 50 mu L, 25 mu L, 12.5 mu L, 7.5 mu L and 3.75 mu L. Setting blank cell control and taurolidine cytotoxicity control, and repeating for 3 times;

placing the inoculated cell plate at 37 ℃ and CO₂In the incubator, the culture was continued and the cytopathic effect was observed.

Third, experimental results

According to the above experimental method, CO is maintained at 37 deg.C₂The cell state was observed in the incubator for 72 hours, and the cell state was good and no cytopathic effect was observed under the microscope in the case of 50. mu.L and 25. mu.L of the drug as the inoculum dose. The cytopathic effect of 12.5. mu.L, 7.5. mu.L and 3.75. mu.L appeared to different degrees, and the inoculation dose of 3.75. mu.L was used as the group and 200TCID was used₅₀The cytopathic effect was not different.

Fourthly, judging the result

Based on the above experimental results, it was determined that 200TCID was completely inhibited when the drug was administered in a dose of 50. mu.L or 25. mu.L₅₀200TCID was not completely inhibited by 12.5. mu.L, 7.5. mu.L of the inoculum dose₅₀Virus-infected cells failed to inhibit 200TCID at an inoculum dose of 3.75. mu.L₅₀The virus infects the cells.

It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications therefrom are within the scope of the invention.

Claims

1. An application of taurolidine in inhibiting HPV virus is disclosed.

2. An application of taurolidine in preparing anti-HPV virus medicine.

3. Use according to claim 2, characterized in that taurolidine is used in the preparation of a medicament for the treatment of cervical epithelial neoplasia, vaginitis, cervical erosion, cervical polyps, cervical cancer or condyloma acuminata caused by HPV viral infection.

4. The use of claim 2 or 3, wherein the taurolidine is in the form of an injection, infusion, tablet or capsule.

5. The use of claim 4, wherein said taurolidine is in the form of an infusion solution.